Stock Monitor: Cytokinetics Post Earnings Reporting
LONDON, UK / ACCESSWIRE / April 30, 2018 / Active-Investors.com has just released a free research report on Zealand Pharma A/S (NASDAQ: ZEAL) ("Zealand"). If you want access to this report all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=ZEAL as the Company's latest news hit the wire. On April 26, 2018, the Company announced that it has successfully concluded the End-of-Phase-2 meeting with the US Food and Drug Administration (FDA) regarding the Phase-3 program for Zealand's long-acting GLP-2 analog, glepaglutide, in short bowel syndrome (SBS) patients. Register today and get access to over 1000 Free Research Reports by joining our site below:
Active-Investors.com is currently working on the research report for Cytokinetics, Incorporated (NASDAQ: CYTK), which also belongs to the Healthcare sector as the Company Zealand Pharma. Do not miss out and become a member today for free to access this upcoming report at:
Active-Investors.com is focused on giving you timely information and the inside line on companies that matter to you. This morning, Zealand Pharma most recent news is on our radar and our team decided to put out a fantastic report on the company that is now available for free below:
Zealand to Initiate Phase-3 Trial in Q3 2018
The outcome of the meeting confirms the path forward for the glepaglutide Phase-3 program. The pivotal Phase-3 trial will be randomized, double-blind, and placebo controlled with once-weekly and twice-weekly dosing regimens. The trial will enroll around 130 patients at multiple sites across the US, EU, and Canada. Zealand expects to initiate the pivotal Phase-3 trial in Q3 2018.
Acceptance by the FDA to Proceed into Phase-3 is an Important Step Forward for Zealand
Commenting on the announcement, Britt Meelby Jensen, President and Chief Executive Officer of Zealand, stated that the Company is encouraged by the positive outcome of the End-of-Phase 2 meeting regarding glepaglutide for treatment of short bowel syndrome. Britt added that the acceptance by the FDA to proceed into Phase-3 is an important step forward for Zealand and for patients suffering from short bowel syndrome.
Glepaglutide Met Primary Endpoint in Phase-2 Trial in Patients with SBS
In June 2017, the Company announced positive results from the Phase-2 trial of glepaglutide in adult patients with SBS. The trial investigated the effect of three different once-daily doses of glepaglutide (10 mg, 1 mg, and 0.1 mg). A total of 16 SBS patients completed the trial. The first dose was administered over a three-week period, followed by a washout period of four weeks and then treatment with the second dose for a further three weeks. The aim was to assess the efficacy, safety and tolerability of different doses of glepaglutide in SBS patients. The primary trial objective was the effect of glepaglutide on patients' intestinal absorptive capacity, measured as reduction in wet weight fecal output. Glepaglutide successfully met the primary study endpoint of reducing fecal wet weight output, with 833 grams/day and 593 grams/day in the 10 mg and 1 mg dose groups, corresponding to a relative decrease of 30% and 23%, respectively. In addition, glepaglutide also appeared to increase energy absorption for the combined 10 mg and 1 mg dose group. Pharmacokinetic data confirmed the long half-life of glepaglutide when dosed daily.
About Short Bowel Syndrome
Short bowel syndrome (SBS) is a malabsorption disorder caused by a lack of functional small intestine. The primary symptom is diarrhea, which can result in dehydration, malnutrition, and weight loss. Other symptoms may include bloating, heartburn, feeling tired, lactose intolerance, and foul-smelling stool. Complications can include anemia and kidney stones. Most cases are due to the surgical removal of a large portion of the small intestine. This is most often required due to Crohn's disease in adults and necrotizing enterocolitis in young children. The most severely affected people are dependent on daily parenteral support. This requires them to be connected to infusion lines and pumps, which pose significant restrictions on their ability to engage in daily activities.
Glepaglutide is a long-acting GLP-2 analog in development for the treatment of SBS. The trial investigates the potential for less than once-daily dosing. The FDA has granted an orphan drug designation to glepaglutide for the treatment of the SBS.
About Zealand Pharma A/S
Founded in 1998 and headquartered in Copenhagen, Denmark, Zealand Pharma is a biotechnology company focused on the discovery, design, and development of innovative peptide-based medicines. Zealand has a portfolio of medicines and product candidates under licence collaborations with Sanofi, Boehringer Ingelheim, and Helsinn.
Stock Performance Snapshot
April 27, 2018 - At Friday's closing bell, Zealand Pharma's stock declined 1.98%, ending the trading session at $14.86.
Volume traded for the day: 2.92 thousand shares.
Stock performance for year-to-date - up 9.26%
After last Friday's close, Zealand Pharma's market cap was at $423.18 million.
The stock is part of the Healthcare sector, categorized under the Biotechnology industry. This sector was up 0.4% at the end of the session.
Active-Investors (A-I) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. A-I has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
A-I has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email firstname.lastname@example.org. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by A-I. A-I is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
A-I, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. A-I, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, A-I, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither A-I nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://active-investors.com/legal-disclaimer/.
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Phone number: 73 29 92 6381
Office Address: 6, Jalan Kia Peng, Kuala Lumpur, 50450 Kuala Lumpur, Wilayah Persekutuan Kuala Lumpur, Malaysia
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.